Pyxis Oncology, Inc.
PYXS
$1.34
$0.021.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.51% | -28.10% | -21.79% | -47.28% | -12.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.26% | 6.91% | 6.98% | -6.90% | 10.06% |
| Operating Income | 1.34% | -366.06% | -6.98% | 6.90% | -10.06% |
| Income Before Tax | -4.45% | -549.82% | -141.94% | 8.01% | -8.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.09% | -549.82% | -128.06% | 8.01% | -8.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.09% | -549.82% | -128.06% | 8.01% | -8.80% |
| EBIT | 1.34% | -366.06% | -6.98% | 6.90% | -10.06% |
| EBITDA | 1.11% | -492.06% | -8.12% | 7.90% | -10.02% |
| EPS Basic | -3.64% | -445.83% | -65.61% | 37.39% | 30.95% |
| Normalized Basic EPS | -2.07% | -445.59% | 21.94% | 37.36% | 30.98% |
| EPS Diluted | -3.64% | -445.83% | -65.61% | 37.39% | 30.95% |
| Normalized Diluted EPS | -2.07% | -445.59% | 21.94% | 37.36% | 30.98% |
| Average Basic Shares Outstanding | 2.35% | 19.03% | 37.70% | 46.90% | 57.59% |
| Average Diluted Shares Outstanding | 2.35% | 19.03% | 37.70% | 46.90% | 57.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |